What do we know about the safety of corticosteroids in rheumatoid arthritis?

Current Medical Research and Opinion

Volumn 29, Issue 9, 2013, Pages 1147-1160

  Ethgen, Olivier ^a   De Lemos Esteves, Frédéric ^b   Bruyere, Olivier ^a   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Corticosteroids; Observational research; Review; Rheumatoid arthritis; Safety

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB;

AMNESIA; BONE DENSITY; BRAIN DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; CUSHINGOID SYNDROME; DERMATOPHYTOSIS; DIGESTIVE SYSTEM PERFORATION; DISEASE DURATION; DIVERTICULITIS; DRUG SAFETY; ECCHYMOSIS; EPISTAXIS; HERPES ZOSTER; HIP FRACTURE; HUMAN; HYPERGLYCEMIA; INTERSTITIAL LUNG DISEASE; KIDNEY DYSFUNCTION; LONGITUDINAL STUDY; LOWER RESPIRATORY TRACT INFECTION; LYMPHOMA; MENTAL DISEASE; METABOLIC SYNDROME X; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; ONSET AGE; OSTEOLYSIS; OSTEOPOROSIS; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; RISK FACTOR; SCAR; SIDE EFFECT; SLEEP DISORDER; SPINE FRACTURE; SYSTEMATIC REVIEW; TINEA PEDIS; TUBERCULOSIS; VASCULITIS; WEIGHT GAIN;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MEDLINE;

EID: 84882771769     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.818531     Document Type: Review

References (102)

1. Dixon WG, Bansback, N. Understanding the side effects of glucocorticoid therapy: Shining a light on a drug everyone thinks they know. Ann Rheum Dis 2012;71:1761-4
2. Lim SS, Conn DL. The use of low-dose prednisone in the management of rheumatoid arthritis. Bull Rheum Dis 2001;50:1-4
3. Kirwan Jr. Systemic low-dose glucocorticoid treatment in rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:389-403, ix-x
4. Saag KG. Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. Arthritis Rheum 2001;45:468-71
5. Saag KG. Glucocorticoid use in rheumatoid arthritis. Curr Rheumatol Rep 2002;4:218-25
6. Pincus T, Sokka T, Stein CM. Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med 2002;136:76-8
7. Townsend HB, Saag KG. Glucocorticoid use in rheumatoid arthritis: Benefits, mechanisms, and risks. Clin Exp Rheumatol 2004;22:S77-82
8. Strand V, Simon LS. Low dose glucocorticoids in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S186-90
9. Boers M. Glucocorticoids in rheumatoid arthritis: A senescent research agenda on the brink of rejuvenatioñBaillieres Best Pract Res Clin Rheumatol 2004;18:21-9
10. Jacobs JW, Bijlsma JW. Glucocorticoids in rheumatoid arthritis: Lessons from the Utrecht study. Clin Exp Rheumatol 2011;29:S59-62
11. Pincus T, Castrejon I, Sokka T. Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: Personal experience over 25 years. Clin Exp Rheumatol 2011;29:S130-8
12. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12 [summary for patients in Ann Intern Med 2002;136:I-26]
13. Kirwan JR, Hallgren R, Mielants H, et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis 2004;63:688-95
14. Pincus T. The clinical efficacy of 3 mg/day prednisone in patients with rheumatoid arthritis: Evidence from a randomized, double-blind, placebocontrolled withdrawal clinical trial. Clin Exp Rheumatol 2011;29:S73-6
15. Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum 2005;52:3360-70
16. Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:3371-80
17. Wassenberg S, Rau R, Zeidler H; Low-Dose Prednisolone Trial G. A dose of only 5mg prednisolone daily retards radiographic progression in early rheumatoid arthritis - the Low-Dose Prednisolone Trial. Clin Exp Rheumatol 2011;29:S68-72
18. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: A randomized trial. Ann Intern Med 2012;156:329-39 [summary for patients in Ann Intern Med 2012;156:I18]
19. Conn DL, Lim SS. New role for an old friend: Prednisone is a disease-modifying agent in early rheumatoid arthritis. Curr Opin Rheumatol 2003;15:193-6
20. Bijlsma JW, van der Goes MC, Hoes JN, et al. Low-dose glucocorticoid therapy in rheumatoid arthritis: An obligatory therapy. Ann N Y Acad Sci 2010;1193:123-6
21. Hoes JN, Jacobs JW, Buttgereit F, et al. Current view of glucocorticoid cotherapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010;6:693-702
22. Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 2000;27:2582-9
23. de Nijs RN, Jacobs JW, Bijlsma JW, et al. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2001;40:1375-83
24. Kroot EJ, Nieuwenhuizen MG, de Waal Malefijt MC, et al. Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum 2001;44:1254-60
25. Roldan JF, Del Rincon I, Escalante A. Loss of cortical bone from the metacarpal diaphysis in patients with rheumatoid arthritis: Independent effects of systemic inflammation and glucocorticoids. J Rheumatol 2006;33:508-16
26. van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the longterm risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3104-12
27. Oelzner P, Schwabe A, Lehmann G, et al. Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Rheumatol Int 2008;28:1143-50
28. Lee SG, Park YE, Park SH, et al. Increased frequency of osteoporosis and BMD below the expected range for age among South Korean women with rheumatoid arthritis. Int J Rheum Dis 2012;15:289-96
29. del Rincon I, O'Leary DH, Haas RW, et al. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004;50:3813-22 [erratum appears in Arthritis Rheum 2005;52:678]
30. Davis 3rd JM, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2007;56:820-30
31. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008;47:72-5
32. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis. Arthritis Rheum 2008;58:2612-21
33. Myasoedova E, Crowson CS, Nicola PJ, et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011;38: 1601-6
34. Franklin J, Lunt M, Bunn D, et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007;66:308-12
35. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic diseasemodifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1074-81
36. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008;35:387-93
37. Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: A nested case-control analysis. Ann Rheum Dis 2012;71:1128-33
38. Dixon WG, Kezouh A, Bernatsky S, et al. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: A nested case-control study. Ann Rheum Dis 2011;70:956-60
39. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006;45:1370-5
40. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57:1431-8
41. Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009;61:300-4
42. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004;49:139-41
43. Douglas KM, Ladoyanni E, Treharne GJ, et al. Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions. Ann Rheum Dis 2006;65:1341-5
44. Curtis JR, Xie F, Chen L, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum 2011;63:346-51
45. Coyne P, Hamilton J, Heycock C, et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 2007;34:1832-6
46. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009;68:1119-24
47. Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: A meta-analysis. Ann Rheum Dis 2009;68:1833-8
48. Ravindran V, Rachapalli S, Choy EH. Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: A meta-analysis. Rheumatology (Oxford) 2009;48:807-11
49. Lee YH, Woo JH, Choi SJ, et al. Effects of low-dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis: A meta-analysis. J Investig Med 2008;56:1011-18
50. Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Infections induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review. Joint Bone Spine 2010;77:246-51
51. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: Systematic review and meta-analyses. Arthritis Res Ther 2011;13:R139
52. Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review. Joint Bone Spine 2011;78:23-30
53. Morrison E, Crosbie D, Capell HA. Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. Rheumatology (Oxford) 2003;42:1247-50
54. van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: An exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010;69:1015-21
55. Augustsson J, Eksborg S, Ernestam S, et al. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1462-6
56. Carter JD, Zarabadi SA, Ricca LR, et al. A safety analysis of oral prednisone as a pretreatment for rituximab in rheumatoid arthritis. Clin Rheumatol 2012;31:1605-10
57. Katayama K, Matsuno T. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: A retrospective study. Clin Drug Invest 2008;28:149-58
58. Morishita M, Nagashima M, Wauke K, et al. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. J Rheumatol 2008;35:407-13
59. Uchida K, Nakajima H, Miyazaki T, et al. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: A prospective study. J Nucl Med 2009;50:1808-14
60. Phillips K, Aliprantis A, Coblyn J. Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis. Drugs Aging 2006;23:773-9
61. Schett G, Saag KG, Bijlsma JW. From bone biology to clinical outcome: State of the art and future perspectives. Ann Rheum Dis 2010;69:1415-19
62. Maricic M. Update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 2011;37:415-31, vi
63. Solomon DH, Katz JN, Jacobs JP, et al. Management of glucocorticoidinduced osteoporosis in patients with rheumatoid arthritis: Rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 2002;46:3136-42
64. Chantler IW, Davie MW, Evans SF, et al. Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis 2003;62:350-2
65. Feldstein AC, Elmer PJ, Nichols GA, et al. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005;16: 2168-74
66. Cruse LM, Valeriano J, Vasey FB, et al. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 2006;12:221-5
67. Ledwich LJ, Clarke K. Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice. J 2009;15:61-4
68. Caplan L, Hines AE, Williams E, et al. An observational study of glucocorticoidinduced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis. Osteoporos Int 2011;22:305-15
69. McKeown E, Bykerk VP, De Leon F, et al. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: Results from the CATCH cohort. Rheumatology (Oxford) 2012;51:1662-9
70. Nishimura J, Ikuyama S. Glucocorticoid-induced osteoporosis: Pathogenesis and management. J Bone Miner Metab 2000;18:350-2
71. Gazi IF, Boumpas DT, Mikhailidis DP, et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: The rationale for using statins. Clin Exp Rheumatol 2007;25:102-11
72. Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008;47:1286-98
73. Housden MM, Bell G, Heycock CR, et al. How to reduce morbidity and mortality from chest infections in rheumatoid arthritis. Clin Med 2010;10:326-9
74. Tierney M, Fraser A, Kennedy N. Cardiovascular risk, inflammation and physical activity in rheumatoid arthritis. Curr Rheumatol Rev 2012;8:180-6
75. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013;52:53-61
76. Jacobs JW, Geenen R, Evers AW, et al. Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis. Ann Rheum Dis 2001;60:61-4
77. Bicer A, Tursen U, Cimen OB, et al. Prevalence of dermatophytosis in patients with rheumatoid arthritis. Rheumatol Int 2003;23:37-40
78. Steens SC, Steup-Beekman GM, Bosma GP, et al. The effect of corticosteroid medication on quantitative MR parameters of the brain. Am J Neuroradiol 2005;26:2475-80
79. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007; 36:172-8
80. Coluccia D, Wolf OT, Kollias S, et al. Glucocorticoid therapy-induced memory deficits: Acute versus chronic effects. J Neurosci 2008;28: 3474-8
81. Toms TE, Panoulas VF, Douglas KM, et al. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: A cross-sectional study. Arthritis Res Ther 2008;10:R145
82. Hellgren K, Iliadou A, Rosenquist R, et al. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: Results from a case-control study. Ann Rheum Dis 2010;69:654-9
83. Bernatsky S, Lee JL, Rahme E. Non-Hodgkin's lymphoma - meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology (Oxford) 2007;46:690-4
84. Karstila KL, Rantalaiho VM, Mustonen JT, et al. Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: An 11-year experience from the FIN-RACo Trial. Clin Exp Rheumatol 2010;28:73-8
85. Avina-Zubieta JA, Abrahamowicz M, Choi HK, et al. Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis: A population-based study. Ann Rheum Dis 2011; 70:990-5
86. Kerachian MA, Seguin C, Harvey EJ. Glucocorticoids in osteonecrosis of the femoral head: A new understanding of the mechanisms of action. J Steroid Biochem Mol Biol 2009;114:121-8
87. Shibatani M, Fujioka M, Arai Y, et al. Degree of corticosteroid treatment within the first 2 months of renal transplantation has a strong influence on the incidence of osteonecrosis of the femoral head. Acta Orthop 2008;79:631-6
88. Kirwan J. What about prednisone? It might be the missing ingredient in the ACR recommendations on the treatment of RA. The Rheumatologist 2013;7:19
89. Pincus T. The steroid question: Is prednisone 3 mg/day an appropriate initial and long-term dose for patients with rheumatoid arthritis? The Rheumatologist 2013;7:20-3
90. Pincus T, Sokka T, Castrejon I, et al. Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res (Hoboken) 2013;65:729-36
91. Kirwan J, Power L. Glucocorticoids: Action and new therapeutic insights in rheumatoid arthritis. Curr Opin Rheumatol 2007;19:233-7
92. Morand EF. Effects of glucocorticoids on inflammation and arthritis. Curr Opin Rheumatol 2007;19:302-7
93. Bijlsma JW, Saag KG, Buttgereit F, et al. Developments in glucocorticoid therapy. Rheum Dis Clin North Am 2005;31:1-17, vii
94. Baschant U, Lane NE, Tuckermann J. The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat Rev Rheumatol 2012;8:645-55
95. Spies CM, Bijlsma JW, Burmester GR, et al. Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol 2010;10:302-7
96. Jacobs JW. Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies. Rheumatology (Oxford) 2012;51(Suppl 4):iv27-33
97. Alten R. Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis. Expert Rev 2012;8:123-33
98. Clarke L, Kirwan J. Efficacy, safety and mechanism of action of modifiedrelease prednisone in rheumatoid arthritis. Ther 2012;4:159-66
99. Spies CM, Cutolo M, Straub RH, et al. Prednisone chronotherapy. Clin Exp Rheumatol 2011;29:S42-5
100. Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: Prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 2010;69:1275-80
101. Kirwan J, Buttgereit F. Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis. Rheumatology (Oxford) 2012;51:iv14-20
102. Pisu M, James N, Sampsel S, et al. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:781-8